A multicenter prospective randomized study testing non-inferiority of thalidomide 100 mg/day as compared with 400 mg/day in patients with refractory/relapsed multiple myeloma: Results of the final analysis of the IFM 01-02 study.

被引：0
|
作者：
Yakoub-Agha, I.
Doyen, C.
Hulin, C.
Marit, G.
Voillat, L.
Grosbois, B.
Harousseau, J.
Duguet, C.
Zerbib, R.
Facon, T.
Mary, J.
机构：
[1] CHRU, Lille, France
[2] CHU, Nancy, France
[3] CHU, Bordeaux, France
[4] CHU, Besancon, France
[5] CHU Rennes, Rennes, France
[6] CHU Nantes, F-44035 Nantes 01, France
[7] Pharmion Dvt, Paris, France
[8] CHU, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：427S / 427S
页数：1
相关论文
共 4 条
  • [1] A multicenter prospective randomized study testing non-inferiority of thalidomide 100 mg/day as compared with 400 mg/day in patients with refractory/relapsed multiple myeloma: First results of the final analysis of the IFM 01-02 study.
    Yakoub-Agha, I
    Hulin, C
    Doyen, C
    Benboubker, L
    Voillat, L
    Bouabdallah, K
    Guillerm, G
    Moreau, R
    Maloisel, F
    Stoppa, AM
    Pegourie, B
    Rodon, P
    Dib, M
    Casassus, P
    Slama, B
    Voog, E
    Jardel, H
    Collet, P
    Wettervald, M
    Peny, AM
    Mineur, P
    Duguet, C
    Zerbib, R
    Facon, T
    Mary, JY
    BLOOD, 2005, 106 (11) : 110A - 110A
  • [2] Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma
    Usmani, Saad Z.
    Nahi, Hareth
    Legiec, Wojciech
    Grosicki, Sebastian
    Vorobyev, Vladimir
    Spicka, Ivan
    Hungria, Vania
    Korenkova, Sibirina
    Bahlis, Nizar J.
    Flogegard, Max
    Blade, Joan
    Moreau, Philippe
    Kaiser, Martin
    Iida, Shinsuke
    Laubach, Jacob
    Magen, Hila
    Cavo, Michele
    Hulin, Cyrille
    White, Darrell
    De Stefano, Valerio
    Lantz, Kristen
    O'Rourke, Lisa
    Heuck, Christoph
    Delioukina, Maria
    Qin, Xiang
    Nnane, Ivo
    Qi, Ming
    Mateos, Maria-Victoria
    HAEMATOLOGICA, 2022, 107 (10) : 2408 - 2417
  • [3] The combination of pegylated liposomal doxorubicin and bortezomib significantly improves time to progression of patients with relapsed/refractory multiple myeloma compared with bortezomib alone: Results from a planned interim analysis of a randomized phase III study.
    Orlowski, Robert Z.
    Zhuang, Sen H.
    Parekh, Trilok
    Xiu, Liang
    Harousseau, Jean-Luc
    BLOOD, 2006, 108 (11) : 124A - 124A
  • [4] Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba
    Mateos, Maria-Victoria
    Usmani, Saad Z.
    Grosicki, Sebastian
    Vorobyev, Vladimir I.
    Spicka, Ivan
    Hungria, Vania T. M.
    Korenkova, Sibirina
    Bahlis, Nizar
    Flogegard, Max
    Blade, Joan
    Moreau, Philippe
    Kaiser, Martin F.
    Iida, Shinsuke
    Laubach, Jacob P.
    Masterson, Tara
    Lantz, Kristen Anne
    O'Rourke, Lisa
    Qin, Xiang
    Parasrampuria, Dolly A.
    Heuck, Christoph
    Qi, Ming
    Nahi, Hareth
    BLOOD, 2019, 134
1